Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jacqueline McBride"'
Autor:
Jacqueline McBride, Bartosz Korczowksi, K T Park, Gaohong She, Astrid Scalori, Regan Li, Jaroslaw Kierkus, Franklin Fuh, AK Kadva, Mariam Abouhossein, Meina Tao Tang, Wenhui Zhang
Publikováno v:
Inflammatory Bowel Diseases. 28:1348-1356
Background Etrolizumab, a humanized anti-β7 antibody, has not been studied in children. Here, we evaluate the pharmacokinetics, pharmacodynamics, and safety of etrolizumab in children with inflammatory bowel disease. Methods Patients age 4 to 17 yea
Autor:
Jacqueline McBride, Melicent C. Peck, Priscilla Horn, Priya Kulkarni, Jeremy J. Lim, Jorge A. Tavel, Gaohong She, Rong Deng, Aide Castro, Elizabeth M. Newton, William D. Hanley, Mauricio Maia
Publikováno v:
Journal of Clinical Pharmacology
MHAA4549A is a human anti‐influenza A monoclonal antibody developed to treat influenza A. We report MHAA4549A serum, nasopharyngeal, and tracheal aspirate pharmacokinetics from a phase 2b study in hospitalized patients with severe influenza A. Pati
Autor:
Amrita Krishnan, Eric W. Humke, Jacqueline McBride, Andrew Polson, Sikander Ailawadhi, Asher Chanan-Khan, Ralph V. Boccia, James Scott McClellan, Jochen Brumm, Seema Singhal, Vanitha Ramakrishnan, Kyu Hong, Douglas D. Leipold, A. Keith Stewart, Quyen Shon-Nguyen, Kirsten Mundt, Jesus G. Berdeja, Ruben Niesvizky, Divya Samineni, Manish R. Patel, Yuanyuan Xiao
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 2, Pp 1-12 (2019)
Blood Cancer Journal, Vol 9, Iss 2, Pp 1-12 (2019)
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
Autor:
Jacqueline McBride, Jorge A. Tavel, Mauricio Maia, X. Charlene Liao, William D. Hanley, Rong Deng, Yehong Wang, Tracy Burgess
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
RG7667, a novel combination of two anticytomegalovirus (anti-CMV) monoclonal IgG1 antibodies (MCMV5322A and MCMV3068A), was designed to block CMV entry into host cells. It was developed as a potential therapy for preventing CMV infection and disease
Autor:
Carrie M. Rosenberger, Dimitri Fillos, Maikke B. Ohlson, Jacqueline McBride, Tracy Burgess, Jeffrey M. Harris, Hosnieh Fathi, Jeremy J. Lim, Rob Lambkin-Williams, Michael A. Derby, Omer Siddiqui, Daniel Sheinson, Rong Deng, Jorge A. Tavel, Haiyin Chen-Harris, Priscilla Horn, Mauricio Maia, Denise Nazzal, Elizabeth M. Newton
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
MHAA4549A, a human monoclonal antibody targeting the hemagglutinin stalk region of influenza A virus (IAV), is being developed as a therapeutic for patients hospitalized with severe IAV infection. The safety and efficacy of MHAA4549A were assessed in
Autor:
C. Andrew Boswell, Rong Deng, Maya Leabman, Daniela Bumbaca, David West, Henry Chiu, Cinthia V. Pastuskovas, Jacqueline McBride, Suhasini Iyer, Hartmut Koeppen, Kyra J. Cowan, Clarissa Johnson, Yan Xin
Publikováno v:
mAbs. 8(3)
MPDL3280A is a human monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1), and exerts anti-tumor activity mainly by blocking PD-L1 interaction with programmed cell death-1 (PD-1) and B7.1. It is being investigated as a potential
Autor:
Romeo Maciuca, Alexander R. Abbas, Jorn Drappa, William P Kennedy, Michael J. Townsend, Jenny Jiang, Alyssa Morimoto, Daniel J. Wallace, Jing Li, Jacqueline McBride
Publikováno v:
Arthritis & Rheumatism. 64:3666-3676
Objective. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies and inflammation in multiple organ systems. Elevation of messenger RNA levels of interferon (IFN)–regulated genes (IRGs) h
Autor:
Dongwei Li, Allen J. Ebens, Ruth M. de Tute, Andrew Jack, Xiaoyan Shi, Saileta Prabhu, Kristi Elkins, William Ho, Jacqueline McBride, Vanitha Ramakrishnan, Randall C. Dere, Andrew Polson, Bing Zheng, Yu-Waye Chu, Andy C. Rawstron, David Dornan, Shang-Fan Yu, Dimitry M. Danilenko, Denise Nazzal, Marna Williams, Katherine R. Kozak, Franklin Fuh, MaryAnn Go, Pamela Chan, Kirsten Achilles Poon, Rong Deng, Josefa Chuh, Jeffrey Lau
Publikováno v:
Molecular cancer therapeutics. 12(7)
Antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antigen with ex